Skip to Main Content

Gilead Sciences’ (GILD) new CEO Daniel O’Day is an A-list pharma veteran, one of the industry’s most successful marketers of cancer drugs, and a decent dealmaker — three qualities the struggling biotech needs to start growing again.

O’Day, the longtime Roche executive most recently in charge of its pharmaceuticals group, was named Gilead’s new CEO on Monday, the company announced. He will start on March 1, 2019, and replace John Milligan, who is leaving at the end of the year after announcing his retirement in July. O’Day’s new job was reported first by the Wall Street Journal on Sunday night.


Investors should be generally happy with O’Day’s selection. Here are three reasons why he’s a solid choice to run Gilead.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.